Announcing a new publication for Acta Materia Medica journal. Cuproptosis is a newly identified specific form of programmed cell death. This study aims to identify cuproptosis-related genes (CRGs) in patients with kidney renal clear cell carcinoma (KIRC) from the Cancer Genome Atlas database and to evaluate CRG biological functions. Using lasso regression, four KIRC prognosis-associated CRGs were identified and an associated prognostic risk signature was constructed. Kaplan-Meier curves showed that patients with high-risk scores had significantly lower survival times than patients with low-risk scores. Multivariate Cox analysis identified MTF1 and FDX1 as two independent overall survival CRGs. Moreover, qRT-PCR showed that MTF1 and FDX1 expression was downregulated in KIRC and knockdown of MTF1 and FDX1 significantly promoted KIRC cell proliferation and migration ability. In addition, the MTF1 level was positively correlated with immune cell infiltration and knockdown of MTF1 promoted tumor growth in vivo. A signature of prognostic risk-associated CRGs was developed that accurately predicted the prognostic status of KIRC patients. MTF1 and FDX1 were shown to be key CRGs. MTF1 acts as a tumor suppressor and may be involved in the progression of KIRC by inhibiting proliferation and regulating immune cell infiltration.
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to email@example.com.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Weipu Mao, Zhou Ding and Keyi Wang et al. Cuproptosis-related MTF1 inhibits kidney renal clear cell carcinoma progression by suppressing proliferation and regulating immune cell infiltration. Acta Materia Medica. 2023. Vol. 2(3):310-322. DOI: 10.15212/AMM-2023-0016